Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 1
2014 1
2015 3
2016 1
2018 1
2019 2
2021 1
2022 4
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

15 results

Results by year

Filters applied: . Clear all
Page 1
Oncolytic virus therapy: A new era of cancer treatment at dawn.
Fukuhara H, Ino Y, Todo T. Fukuhara H, et al. Cancer Sci. 2016 Oct;107(10):1373-1379. doi: 10.1111/cas.13027. Epub 2016 Sep 9. Cancer Sci. 2016. PMID: 27486853 Free PMC article. Review.
Other oncolytic viruses that are closing in on drug approval in North America and Europe include vaccinia virus JX-594 (pexastimogene devacirepvec) for hepatocellular carcinoma, GM-CSF-expressing adenovirus CG0070 for bladder cancer, and Reolysin (pelareorep), a wil …
Other oncolytic viruses that are closing in on drug approval in North America and Europe include vaccinia virus JX-594 (pexastimogene …
Vaccinia-based oncolytic immunotherapy Pexastimogene Devacirepvec in patients with advanced hepatocellular carcinoma after sorafenib failure: a randomized multicenter Phase IIb trial (TRAVERSE).
Moehler M, Heo J, Lee HC, Tak WY, Chao Y, Paik SW, Yim HJ, Byun KS, Baron A, Ungerechts G, Jonker D, Ruo L, Cho M, Kaubisch A, Wege H, Merle P, Ebert O, Habersetzer F, Blanc JF, Rosmorduc O, Lencioni R, Patt R, Leen AM, Foerster F, Homerin M, Stojkowitz N, Lusky M, Limacher JM, Hennequi M, Gaspar N, McFadden B, De Silva N, Shen D, Pelusio A, Kirn DH, Breitbach CJ, Burke JM. Moehler M, et al. Oncoimmunology. 2019 Jun 3;8(8):1615817. doi: 10.1080/2162402X.2019.1615817. eCollection 2019. Oncoimmunology. 2019. PMID: 31413923 Free PMC article.
Pexastimogene devacirepvec (Pexa-Vec) is a vaccinia virus-based oncolytic immunotherapy designed to preferentially replicate in and destroy tumor cells while stimulating anti-tumor immunity by expressing GM-CSF. ...
Pexastimogene devacirepvec (Pexa-Vec) is a vaccinia virus-based oncolytic immunotherapy designed to preferentially replicate i …
Oncolytic Virotherapy and Gene Therapy Strategies for Hepatobiliary Cancers.
Yamada T, Hamano Y, Hasegawa N, Seo E, Fukuda K, Yokoyama KK, Hyodo I, Abei M. Yamada T, et al. Curr Cancer Drug Targets. 2018;18(2):188-201. doi: 10.2174/1568009617666170330123841. Curr Cancer Drug Targets. 2018. PMID: 28359239 Review.
Numerous OVs are being tested in preclinical models of hepatocellular carcinoma (HCC). The lead agent Pexa-Vec (pexastimogene devacirepvec, JX-594), a recombinant Wyeth strain vaccinia virus, has demonstrated preliminary evidence of safety and efficacy for HCC in cl …
Numerous OVs are being tested in preclinical models of hepatocellular carcinoma (HCC). The lead agent Pexa-Vec (pexastimogene deva …
Oncolytic virus therapy in Japan: progress in clinical trials and future perspectives.
Taguchi S, Fukuhara H, Todo T. Taguchi S, et al. Jpn J Clin Oncol. 2019 Mar 1;49(3):201-209. doi: 10.1093/jjco/hyy170. Jpn J Clin Oncol. 2019. PMID: 30462296 Review.
Other oncolytic viruses using different parental viruses have also been tested in Phase III clinical trials and are ready for drug approval: Pexa-Vec (pexastimogene devacirepvec), an oncolytic vaccinia virus, CG0070, an oncolytic adenovirus, and REOLYSIN (pelareorep …
Other oncolytic viruses using different parental viruses have also been tested in Phase III clinical trials and are ready for drug approval: …
The emerging therapeutic potential of the oncolytic immunotherapeutic Pexa-Vec (JX-594).
Breitbach CJ, Bell JC, Hwang TH, Kirn DH, Burke J. Breitbach CJ, et al. Oncolytic Virother. 2015 Jan 28;4:25-31. doi: 10.2147/OV.S59640. eCollection 2015. Oncolytic Virother. 2015. PMID: 27512667 Free PMC article. Review.
Here we review preclinical and clinical experience with Pexa-Vec (pexastimogene devacirepvec, JX-594). Pexa-Vec is derived from a vaccinia vaccine strain that has been engineered to target cancer cells and express the therapeutic transgene granulocyte macrophage col …
Here we review preclinical and clinical experience with Pexa-Vec (pexastimogene devacirepvec, JX-594). Pexa-Vec is derived fro …
Oncolytic virus-based hepatocellular carcinoma treatment: Current status, intravenous delivery strategies, and emerging combination therapeutic solutions.
Li X, Sun X, Wang B, Li Y, Tong J. Li X, et al. Asian J Pharm Sci. 2023 Jan;18(1):100771. doi: 10.1016/j.ajps.2022.100771. Epub 2022 Dec 29. Asian J Pharm Sci. 2023. PMID: 36896445 Free PMC article. Review.
OVs undergo selective replication in cancerous tissues and kill tumor cells. Strikingly, pexastimogene devacirepvec (Pexa-Vec) was granted an orphan drug status in HCC by the U.S. ...
OVs undergo selective replication in cancerous tissues and kill tumor cells. Strikingly, pexastimogene devacirepvec (Pexa-Vec) …
Phase I/II study of PexaVec in combination with immune checkpoint inhibition in refractory metastatic colorectal cancer.
Monge C, Xie C, Myojin Y, Coffman K, Hrones DM, Wang S, Hernandez JM, Wood BJ, Levy EB, Juburi I, Hewitt SM, Kleiner DE, Steinberg SM, Figg WD, Redd B, Homan P, Cam M, Ruf B, Duffy AG, Greten TF. Monge C, et al. J Immunother Cancer. 2023 Feb;11(2):e005640. doi: 10.1136/jitc-2022-005640. J Immunother Cancer. 2023. PMID: 36754451 Free PMC article. Clinical Trial.
Here, we evaluated the safety and efficacy of the combination of pexastimogene devacirepvec (PexaVec) plus durvalumab (anti-programmed death ligand 1) with and without tremelimumab (anti-cytotoxic T-lymphocyte associated protein 4) in patients with standard chemothe …
Here, we evaluated the safety and efficacy of the combination of pexastimogene devacirepvec (PexaVec) plus durvalumab (anti-pr …
Neoadjuvant Intravenous Oncolytic Vaccinia Virus Therapy Promotes Anticancer Immunity in Patients.
Samson A, West EJ, Carmichael J, Scott KJ, Turnbull S, Kuszlewicz B, Dave RV, Peckham-Cooper A, Tidswell E, Kingston J, Johnpulle M, da Silva B, Jennings VA, Bendjama K, Stojkowitz N, Lusky M, Prasad KR, Toogood GJ, Auer R, Bell J, Twelves CJ, Harrington KJ, Vile RG, Pandha H, Errington-Mais F, Ralph C, Newton DJ, Anthoney A, Melcher AA, Collinson F. Samson A, et al. Cancer Immunol Res. 2022 Jun 3;10(6):745-756. doi: 10.1158/2326-6066.CIR-21-0171. Cancer Immunol Res. 2022. PMID: 35439304 Free PMC article.
Improving the chances of curing patients with cancer who have had surgery to remove metastatic sites of disease is a priority area for cancer research. Pexa-Vec (Pexastimogene Devacirepvec; JX-594, TG6006) is a principally immunotherapeutic oncolytic virus that has …
Improving the chances of curing patients with cancer who have had surgery to remove metastatic sites of disease is a priority area for cance …
Efficacy and safety of oncolytic viruses in advanced or metastatic cancer: a network meta-analysis.
Xie R, Bi X, Shang B, Zhou A, Shi H, Shou J. Xie R, et al. Virol J. 2021 Jul 31;18(1):158. doi: 10.1186/s12985-021-01630-z. Virol J. 2021. PMID: 34332591 Free PMC article.
METHODS: A total of 5948 studies were screened and 13 randomized controlled trials with 1939 patients, of whom 1106 patients received OV therapies, comparing four OVs (NTX-010, pexastimogene devacirepvec (Pexa-Vec), talimogene laherparepvec (T-VEC), and pelareorep) …
METHODS: A total of 5948 studies were screened and 13 randomized controlled trials with 1939 patients, of whom 1106 patients received OV the …
Systemic Injection of Oncolytic Vaccinia Virus Suppresses Primary Tumor Growth and Lung Metastasis in Metastatic Renal Cell Carcinoma by Remodeling Tumor Microenvironment.
Park JS, Lee ME, Jang WS, Kim J, Park SM, Oh K, Lee N, Ham WS. Park JS, et al. Biomedicines. 2022 Jan 14;10(1):173. doi: 10.3390/biomedicines10010173. Biomedicines. 2022. PMID: 35052851 Free PMC article.
Here, we aimed to evaluate the therapeutic efficacy of JX-594 (pexastimogene devacirepvec, Pexa-vec) monotherapy by systemic injection in comparison with sunitinib monotherapy in metastatic orthotopic RCC murine models. ...
Here, we aimed to evaluate the therapeutic efficacy of JX-594 (pexastimogene devacirepvec, Pexa-vec) monotherapy by systemic i …
15 results